Saphris (Schizophrenia) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 44 Pages
|Saphris(精神分裂症):市場預測與分析 Saphris (Schizophrenia) - Forecast and Market Analysis to 2022|
|出版日期: 2014年02月28日||內容資訊: 英文 44 Pages||
本報告提供精神分裂症治療藥之一──Saphris 的全球市場相關分析，提供精神分裂症概要和治療方法，Saphris 商品資訊(特色·功效·安全性等)和競爭力，競爭的企業·藥品概要，全球主要國家的市場販售額預測(今後10年份)等調查，並將結果概述為以下內容。
Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.
Saphris (asenapine maleate), also known as Sycrest in the EU, is a dibenzazepine neuroleptic. The drug utilizes the tricyclic dibenzazepine heterocycle as a basic structural feature which is lipophilic in its nature, allowing Saphris to cross the blood-brain barrier with less resistance. Unlike Abilify, Saphris acts as an antagonist at dopamine D2 receptors, meaning that Saphris can effectively target positive psychotic symptoms associated with schizophrenia; however, it has a higher chance of causing extrapyramidal symptoms over the long term.